ABOUT RWMRF.org
Guy Maxwell Chisolm III, Ph.D.
Department of Cell Biology
The Lerner Research Institute
The Cleveland Clinic Foundation (NC-10)
9500 Euclid Avenue
Cleveland, Ohio 44195
Telephone: (216) 444-5854; Fax: (216) 444-9404; E-mail: chisolg@ccf.org
|
|
PROFESSIONAL APPOINTMENTS
Primary Appointments
1976-present:
Department of Cell Biology, The Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, Adjunct Staff Member (1976-1985), Full Staff Member (1985-present), Interim Chairman (2002-2004)
2003-present:
Vice Chairman of the Lerner Research Institute, Cleveland Clinic Foundation
Other active academic appointments
1975-present:
Department of Biomedical Engineering, School of Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH, Assistant Professor (1975-1981), Associate Professor (with tenure) (1981-1985), Adjunct Associate Professor (1985-1998), Adjunct Professor (2002-2005), Professor, 2005-present)
1996-present:
Department of Chemistry, Cleveland State University, Cleveland, OH, Professor
2002-present:
Department of Biological Sciences, Kent State University, Kent, OH, Professor
2003-present:
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, Joint Staff
2003-present:
Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, Professor
POSTDOCTORAL RESEARCH POSITIONS
1972-1973:
Department of Pharmacology, Karolinska Institute, Stockholm, Sweden, NIH Postdoctoral Fellow; Supervisor: Professor Sune Rosell
1973-1975:
Arteriosclerosis Center and Department of Chemical Engineering, Massachusetts Institute of Technology, Boston, Research Associate; Supervisors: Professors Robert S. Lees and Clark K. Colton
EDUCATION
1964-1968:
B.S., Chemical Engineering, University of Pennsylvania, Philadelphia
1968-1972:
Ph.D. (and M.S.), Chemical Engineering, University of Virginia, Charlottesville; Thesis supervisor: Professor John L. Gainer
FELLOWSHIPS, HONORS AND AWARDS
1964-1968: From U of Pa: Alumni Regional, University Fund, and St. Anthony Fund Scholarships
1968-1972: From U of Va: Memminger Fellowship, University Fellowship, Monsanto Fellowship
1972-1973: From NIH: Postdoctoral Fellowship to Karolinska Institute
1977-1982: From NIH: Research Career Development Award
1995-1997: American Heart Association, Northeast Ohio Affiliate: President
1988-1998: American Heart Association, Northeast Ohio Affiliate, Board of Trustees
1988-2000: American Heart Association, Ohio Valley Affiliate, Board of Directors (1998-2000)
1998-2002: Cleveland Clinic Foundation: Board of Governors
2002-2003: Cleveland Clinic Foundation: Board of Trustees (and Executive Committee)
2002: From American Heart Association, Ohio Valley Affiliate: Science Merit Award (First annual award, given for research impact on cardiovascular diseases)
PEER REVIEW AND ADVISORY FUNCTIONS
1. Review of approximately 30-40 manuscripts annually submitted to the journals listed below. (Listed are journals for which I reviewed manuscripts in recent years; most frequent are in bold):
| American Journal of Clin. Nutr. |
IEEE Transactions in |
| American Journal of Pathology |
Biomedical Engineering |
| American Journal of Physiology |
Immunology Today |
| Annals of Biomedical Engineering |
In Vitro |
| Arteriosclerosis, Thromb & Vasc Biol |
Journal of Biological |
| Artery |
Chemistry |
| Atherosclerosis |
J Cardiovascular Pharmacology |
| Bio Science (book review) |
J Cellular Biochemistry |
| Biochemical Pharmacology |
Journal of Clinical |
| Biochimica et Biophysica Acta |
Investigation |
| Blood |
Journal of Laboratory and Clinical Medicine |
| Cardiovascular Research |
Journal of Lipid Research |
| Circulation |
Journal of Nutrition |
| Circulation Research |
Journal of Vascular Research |
| Diabetes |
Laboratory Investigation |
| Diabetes Care |
Lipids |
| Europ J Clin Invest |
Metabolism |
| Experimental and Molecular Pathology |
Nature Medicine |
| Experimental Cell Research |
Ohio Journal of Science |
| FASEB J. |
Proceedings of the National Academy of Sciences, USA |
| FEBS Letters |
Free Radical Biology and Medicine |
| Hormone and Metabolic Research |
Transfusion |
| Hypertension |
|
| |
|
2. Associate Editor, American Journal of Physiology: Heart and Circulatory Physiology, 1985-86.
Editorial Board, Arteriosclerosis, Thrombosis and Vascular Biology, 1991-2001.
Editorial Board, Journal of Biological Chemistry, 2000-present.
3. Review of applications for research funding for:
NIH: Study Section member (1991-94), Chair (1993-94) of Heart, Lung, and Blood Research Review Committee B (for Program Projects); frequent site visit team member for various Program Project Grant applications (1985-present).
NIH: Study Section member (1996-1999): Metabolism Study Section.
American Heart Association (Dallas): Study Section on Vascular Wall Biology; Co-chair (1991-1993, 1995-1996); (Chair, 1996-1999).
American Heart Association (Dallas): Study Section on Lipoprotein, Lipid Metabolism and Epidemiology Research (1988-1990).
American Heart Association, Northeast Ohio Affiliate: Chairman, Research Allocations Committee (1993-96); past member of Fellowship Review Committee, Research Study Section, and Allocations Committees.
American Heart Association, Southern and Ohio Valley: Study Section for Lipoproteins, Nutrition, Thrombosis and Vascular Biology (2003-2006) (Co-Chair, 2005-2006)
Other: ad hoc review of grants submitted to NIH, NSF, Veteran's Administration, American Diabetes Association, USDA, and various private foundations.
4. Advisory Boards:
NIH: Data Management and Safety Board for "Arterial Disease Multiple Intervention Trial" (ADMIT), 1992-1996.
American Heart Association, Northeast Ohio Affiliate: Board of Trustees, 1988-1998; Ohio Valley Affiliate: Board of Directors, 1998-2000.
Steering Committee, National Working Group on Conflict of Interest, 2005-present
PROFESSIONAL AFFILIATIONS
American Association for the Advancement of Science
American Society for Cell Biology
American Society for Microbiology
Fellow, Council on Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association (National), elected Councilor at Large, 2005-present
American Heart Association, Ohio Valley Affiliate
New York Academy of Science
North American Vascular Biology Organization, elected Councilor, 1999-2001
Fellow, Environmental Health Institute
PUBLICATIONS(Published Abstracts are not included in CV.)
1. Chisolm, G.M., E.N. Terrado and J.L. Gainer: Physiological transport in relation to aging. Nature 230: 390-391, 1971.
2. Chisolm, G.M. and J.L. Gainer: Tube viscometry of blood: effects of wall material. J Appl Physiol 31: 313-317, 1971.
3. Chisolm, G.M., J.L. Gainer, G.E. Stoner and J.V. Gainer, Jr.: Plasma proteins, oxygen transport and atherosclerosis. Atherosclerosis 15: 327-343, 1972.
4. Chisolm, G.M., Stoner, G.E., and Gainer, J.L.: Scanning electron microscope studies of aortic structure. Angiologica 10: 10-14, 1973.
5. Chisolm, G.M., Gainer, J.L., and Ranieri, A.J., Jr.: Proteins and atherosclerosis. Experientia 29: 167-168, 1973.
6. Gainer, J.L. and G.M. Chisolm. Altering diffusion rates. Adv Exp Med Biol 37:729-733, 1973.
7. Colton, C.K., R.L. Bratzler, K.A. Smith, G.M. Chisolm, R.S. Lees and D.B. Zilversmit: Transport of albumin and low-density lipoproteins in the arterial wall. In: Proc. Specialist Mtg. on Fluid Dynamic Aspects of Arterial Disease. (R.M. Nerem, ed), pp 51-54, Ohio State Univ, NSF, 1974.
8. Gainer, J.L. and Chisolm, G.M.: Oxygen diffusion and atherosclerosis. Atherosclerosis 19: 135-138, 1974.
9. Stoner, G.E., G.M. Chisolm, S. Srinivasan, T.R. Lucas and P.N. Sawyer: Vascular injury and thrombosis: a scanning electron microscopic study. Thromb. Res. 4: 699-706, 1974.
10. Rosell, S., M. Intaglietta and G.M. Chisolm: Adrenergic influence on isovolumetric capillary pressure in canine adipose tissue. Amer. J. Physiol. 227: 692-696, 1974.
11. Linde, B, G.M. Chisolm and S. Rosell: The influence of sympathetic activity and histamine on the blood-tissue exchange of solutes in canine adipose tissue. Acta Physiol. Scand. 92: 145-155, 1974.
12. Linde, B. and G.M. Chisolm: The interstitial space of adipose tissue as determined by single injection and equilibration techniques. Acta Physiol. Scand. 95: 383-390, 1975.
13. Pool, J.D., J.L. Gainer and G.M. Chisolm: Oxygen diffusion and atherosclerosis. In: Advances in Experimental Medicine and Biology, Vol 67: Atherosclerosis Drug Discovery, pp 205-211, Plenum Publishing Corp., New York, 1976.
14. Feig, L.A., N.A. Peppas, G.M. Chisolm, C.K. Colton, K.A. Smith and R.S. Lees: Transport of albumin across the aortic wall during acute angiotensin-induced hypertension. Proc. 29th Annual Meeting, ACEMB, p 232, 1976.
15. Schwartz, C.J., R.G. Gerrity, L.J. Lewis, G.M. Chisolm and K.N. Bretherton: Endothelial permeability to macromolecules. In: Atherosclerosis IV (G. Schettler, Y. Gotto, Y. Hata and G. Klose, eds), pp 1-11, Springer-Verlag, Berlin, 1977.
16. Bratzler, R.L., G.M. Chisolm, C.K. Colton, K.A. Smith, D.B. Zilversmit and R.S. Lees: The distribution of labeled albumin across the rabbit thoracic aorta in vivo. Circ. Res. 40: 182-190, 1977.
17. Bratzler, R.L., G.M. Chisolm, C.K. Colton, K.A. Smith and R.S. Lees: The distribution of labeled low-density lipoprotein across the rabbit thoracic aorta in vivo. Atherosclerosis 28: 289-307, 1977.
18. Massaro, T.A., C.E. Glatz, N.A. Peppas, G.M. Chisolm and C.K. Colton: Distribution of glycosaminoglycans in consecutive layers of the rabbit and swine aorta. Artery 5: 1-13, 1979.
19. Hessler, J.R., A.L. Robertson, Jr. and G.M. Chisolm: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32: 213-229, 1979.
20. Gainer, J.L. and G.M. Chisolm: Mass transfer in atherosclerosis. In: Advances in Biomedical Engineering (D.O. Cooney, ed), Vol. 6, Part II, pp 391-426, Marcel Dekker, New York, 1980.
21. Hirsch, E.Z., W. Martino, C. Orr, H. White and G.M. Chisolm: A simple, rapid method for the preparation of en face endothelial (Hautchen) monolayers from rat and rabbit aortas. Atherosclerosis 37: 539-548, 1980.
22. Hirsch, E.Z., G.M. Chisolm and A. Gibbons: Quantitative assessment of changes in aortic dimensions in response to in situ perfusion fixation at physiological pressures. Atherosclerosis 38: 63-74, 1981.
23. Chisolm, G.M., C.A. Sila and S.P. Hmiel: Measurements of the degradation products of radioiodinated proteins. Anal. Biochem. 111: 212-219, 1981.
24. Hirsch, E.Z., G.M. Chisolm and H.M. White: Reendothelialization and maintenance of endothelial integrity in longitudinal denuded tracks in the thoracic aorta of rats. Atherosclerosis 46: 287-307, 1983.
25. Chisolm, G.M., M.P. Bohrer, C.K. Colton, K.A. Smith and R.S. Lees: Transmural 125I-albumin concentration in the rabbit aorta during acute hypoxia. Atherosclerosis 46: 195-202, 1983.
26. Hessler, J.R., D.W. Morel, L.J. Lewis and G.M. Chisolm: Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3: 215-222, 1983.
27. Morel, D.W., J.R. Hessler and G.M. Chisolm: Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J. Lipid Res. 24: 1070-1076, 1983.
28. Alpern, D.B., G.M. Chisolm and L.J. Lewis: The effect of ionophore A23187 on albumin internalization in cultured human umbilical vein endothelial cells. Exp. Cell Res. 149: 555-564, 1983.
29. Morel, D.W., P.E. DiCorleto and G.M. Chisolm: Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 4: 357-364, 1984.
30. Cathcart, M.K., D.W. Morel and G.M. Chisolm III: Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J. Leuk. Biol. 38: 341-350, 1985.
31. Stowe, N.T., M.O. Magnusson, K. Jojima, G.M. Chisolm, A.C. Novick, and R.A. Straffon: Combined use of normobaric oxygen perfusion and simple cold storage for extended kidney preservation. Transplantation Proc. 18: 553-556, 1986.
32. Skrinska, V.A., F.V. Lucas, G.M. Chisolm and B.L. Hesse: Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. J. Lab. Clin. Med. 107: 187-193, 1986.
33. Lucas, F.V., V.A. Skrinska, G.M. Chisolm and B.L. Hesse: Stability of prostacyclin in human and rabbit whole blood and plasma. Thrombosis Res. 43: 379-387, 1986.
34. Morel, D.W., P.E. DiCorleto and G.M. Chisolm: Modulation of endotoxin-induced endothelial cell toxicity by low density lipoprotein. Lab. Invest. 55: 419-426, 1986.
35. DiCorleto, P.E. and G.M. Chisolm III: Participation of the endothelium in the development of the atherosclerotic plaque. Prog. Lipid Res. 25: 365-374, 1986.
36. DiCorleto, P.E., P.L. Fox and G.M. Chisolm: Production of platelet-derived growth factor-like protein by endothelial cells. In: Current Communications in Molecular Biology. Angiogenesis: Mechanisms and Pathology. Cold Spring Harbor Laboratory, pp. 65-68, 1987.
37. Jürgens, G., H.F. Hoff, G.M. Chisolm and H. Esterbauer: Modification of human serum low density lipoprotein by oxidation: Characterization and pathophysiological implications. Chem. Phys. Lipids 45: 315-336, 1987.
38. Saidel, G.M., E.D. Morris and G.M. Chisolm: Transport of macromolecules in arterial wall in vivo: A mathematical model and analytical solutions. Bulletin of Mathematical Biology 49: 153-169, 1987.
39. Kosugi, K., D.W. Morel, P.E. DiCorleto and G.M. Chisolm: Toxicity of oxidized low density lipoprotein to fibroblasts is selective for S phase of the cell cycle. J. Cell. Physiol. 130: 311-320, 1987.
40. Fox, P.L., G.M. Chisolm and P.E. DiCorleto: Lipoprotein-mediated inhibition of endothelial cell production of PDGF-like protein depends on free radical lipid peroxidation. J. Biol. Chem. 262: 6046-6054, 1987.
41. Hoff H.F., G.M. Chisolm, D.W. Morel, G. Jürgens, and H. Esterbauer: Chemical and functional changes in LDL following modification by 4-hydroxynonenal. In: Oxy-radicals in Molecular Biology and Pathology (Cerutti PA, Fredovich I, McCord JM, eds.) Alan R. Liss, Inc., NY, pp 459-472, 1988.
42. Chisolm, G.M. and D.W. Morel: Lipoprotein oxidation and cytotoxicity: effect of probucol in streptozotozin-treated rats. Amer. J. Cardiol. 62: 20B 26B, 1988.
43. Cathcart, M.K., G.M. Chisolm, A.K. McNally and D.W. Morel: Oxidative modification of low density lipoprotein (LDL) by activated human monocytes and the cell lines U937 and HL60. In Vitro Cellular and Developmental Biol. 24: 1001-1008, 1988.
44. DiCorleto, P.E., P.L. Fox, and G.M. Chisolm III. Lipid modulation of growth factor production by aortic endothelial cells. In: Atherosclerosis VIII, Crepaldi, G., Gotto, A.M., Manzato, E. and Baggio, G. (eds.), Elsevier Science Publishers, pp. 91-94, 1989.
45. Cathcart, M.K., A.K. McNally, D.W. Morel and G.M. Chisolm: Superoxide anion participation in human monocyte-mediated oxidation of LDL and conversion of LDL to a cytotoxin. J. Immunol. 142: 1963-1969, 1989.
46. Hoff, H.F., G. Jürgens, G.M. Chisolm, O. Quehenberger and H. Esterbauer: Modification of LDL with 4-hydroxynonenal induces uptake of LDL by macrophages. Arteriosclerosis 9:538-549,1989.
47. Morel, D.W. and G.M. Chisolm: Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J. Lipid Research 30:1827 1833,1989.
48. Hamilton, T.A., G. Ma and G.M. Chisolm: Oxidized low density lipoprotein suppresses the expression of TNF ? mRNA in stimulated murine peritoneal macrophages. J. Immunol. 144:2343-2350, 1990.
49. McNally, A.K., G.M. Chisolm, D.W. Morel and M.K. Cathcart: Activated human monocytes oxidize LDL by a lipoxygenase dependent pathway. J. Immunol. 145:254-259, 1990.
50. Penn, M.S., M.R. Koelle, S.M. Schwartz and G.M. Chisolm: Visualization and quantification of transmural concentration profiles of macromolecules across the arterial wall. Circ. Res. 67:11-22, 1990.
51. Cathcart, M.K., A.K. McNally and G.M. Chisolm: Lipoxygenase-mediated transformation of human low density lipoprotein to an oxidized and cytotoxic complex. J. Lipid Res. 32:63-70, 1991.
52. Penn, M.S. and G.M. Chisolm: The relation between lipopolysaccharide-induced endothelial cell injury and the entry of macromolecules into the rat aorta in vivo. Circ. Res. 68:1259-1269, 1991.
53. Morris, E.D., G.M. Saidel and G.M. Chisolm: Optimal design of experiments to estimate LDL transport parameters in arterial wall. Am. J. Physiol. 261:H929-H949, 1991.
54. Freeman, M., Y. Ekkel, L. Rohrer, M. Penman, N. Freedman, G.M. Chisolm and M. Krieger: Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized LDL. Proc. Natl. Acad. Sci. USA 88:4931-4935, 1991.
55. Chisolm, G.M., P.E. DiCorleto, L.A. Ehrhart, P.L. Fox, H.F. Hoff and R.E. Morton. Pathogenesis of Atherosclerosis. Chapter 7 in: Peripheral Vascular Diseases. Young, J.R., Graor, R.A., Olin, J.W. and Bartholomew, J.R. (eds.), Mosby-Year Book, Inc., St. Louis, MO. pp. 137-160, 1991.
56. Chisolm, G.M. Antioxidants and atherosclerosis: a current assessment. Clin. Cardiol. 14:I25-30, 1991.
57. Chisolm, G.M. Cytotoxicity of oxidized lipoproteins. Current Opinion in Lipidology. 2: 311-316, 1991.
58. Chisolm, G.M. Oxidized Lipoproteins. Chapter 9 in: Plasma Lipoproteins and Coronary Artery Disease. Kreisberg, R.A. and Segrest, J. (eds.), Blackwell Scientific Publications, Boston, MA. pp. 201-222, 1992.
59. Chisolm, G.M., K.C. Irwin and M.S. Penn: Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41: 61-66, 1992.
60. Chisolm, G.M. The oxidation of lipoproteins: implications for atherosclerosis. Chapter 4 in: Biological Consequences of Oxidative Stress: Implications for Cardiovascular Disease and Carcinogenesis. Spatz, L. and Bloom, A.D. (eds.), Oxford University Press, New York, NY. pp. 78-106, 1992.
61. Penn, M. S., G.M. Saidel and G.M. Chisolm: Vascular injury by endotoxin: changes in macromolecular transport parameters in the rat aorta in vivo. Am. J. Physiol. 262:H1563-H1571, 1992.
62. Chisolm, G.M. How does coronary plaque form? One theory explained. Heartline 23: 4-6, 1993.
63. Chisolm, G.M: Oxidized lipoproteins and leukocyte-endothelial interactions: growing evidence for multiple mechanisms. Editorial. Lab. Invest. 68: 369-371, 1993.
64. Chisolm, G.M. Lipoprotein oxidation and cell injury. In: Dietary Lipids, Antioxidants and the Prevention of Atherosclerosis. Ursini, F. and Cadenas, E. (eds.), Cleup, University Publisher, Padova, Italy, pp. 75-82, 1993.
65. Chisolm, G.M.: Possible influences of oxidants and antioxidants in restenosis following angioplasty. In: Restenosis Summit V. Cleveland Clinic Heart Center, Cleveland, OH. pp 170-175, 1993.
66. Murugesan, G., G.M. Chisolm and P.L. Fox: Oxidized low density lipoprotein inhibits the migration of aortic endothelial cells in vitro. J. Cell. Biol., 120:1011-1019, 1993.
67. Penn, M.S., G.M Saidel, G.M. Chisolm: Relative significance of endothelium and internal elastic lamina in regulating the entry of macromolecules into arteries in vivo. Circ. Res., 74:74-82, 1994.
68. Ehrenwald, E., G.M. Chisolm and P.L. Fox: Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J. Clin. Invest., 93:1493-1501, 1994.
69. Chisolm, G.M., G. Ma, K.C. Irwin, L.L. Martin, K.G. Gunderson, L.F. Linberg, D.W. Morel and P.E. DiCorleto: 7?-hydroperoxycholest-5-en-3?-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc. Natl. Acad. Sci. USA., 91:11452-11456, 1994.
70. Penn, M.S. and G.M. Chisolm: Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 108 (Suppl): S21-S29, 1994.
71. Lafont, A.M., Y.-C. Chai, J.F. Cornhill, P.L. Whitlow, P.H. Howe, and G.M. Chisolm: Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J. Clin. Invest, 95: 1018-1025, 1995.
72. Freeman E.J., Chisolm G.M. and Tallant E.A.: Role of calcium and protein kinase C in the activation of phospholipase D by angiotensin II in vascular smooth muscle cells. Arch Biochem Biophys, 319, 84-92, 1995
73. Lafont A., Guzman L., Whitlow P.L., Goormastic M., Cornhill J.F. and Chisolm G.M.: Restenosis after experimental angioplasty: intimal, medial and adventitial changes associated with constrictive remodeling. Circ. Res. 76: 996-1002, 1995.
74. Hamilton T.A., Major J.A., and Chisolm G.M.: The effects of oxidized LDL on inducible mouse macrophage gene expression are gene and stimulus dependent. J. Clin. Invest. 95: 2020-2027, 1995.
75. Cathcart M.K., Li Q., and Chisolm G.M. III: Lipoprotein receptor interactions are not required for monocyte oxidation of LDL. J. Lipid Res. 36: 1857-1865, 1995.
76. Coffey M.D., Cole R.A., Colles S.M., and Chisolm G.M.: In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid and peroxyl radicals. J. Clin. Invest. 96: 1866-1873, 1995.
77. Pushpa-Rekha T.R. Burdsall A.L., Oleksa L.M., Chisolm G.M., Driscoll D.M.: Rat phospholipid hydroperoxide glutathione peroxidase: cDNA cloning and identification of multiple transcription and translation start sites. J. Biol. Chem. 270:26993-26999, 1995.
78. Chisolm, G.M., Irwin, K.C. and DiCorleto, P.E.: Atherosclerosis: Characterization of the disease and underlying mechanisms. In: "Renal Vascular Disease." Editors: A.C. Novick, J. Scoble, and G. Hamilton. W.B. Saunders, Co., London, pp. 3-19, 1996.
79. Chisolm, G.M. and Penn, M.S.: Oxidized lipoproteins and atherosclerosis. In: "Atherosclerosis and Coronary Disease." Editors: V. Fuster, R. Ross, E. Topol. Raven Press, New York, pp 129-149, 1996.
80. DiCorleto, P.E., Hoff, H.F., Ehrhart, L.A., Morton, R.E. and Chisolm, G.M.: Pathogenesis of atherosclerosis. In: "Peripheral Vascular Diseases." Editors: J.R. Young, J.W. Olin, J.R. Bartholomew. Mosby Year Book. Boston. pp 143-165, 1996.
81. Lafont A., Marwick T.H., Chisolm G.M., Van Lente F., Vaska K.J., and Whitlow P.L.: Decreased free radical scavengers with reperfusion following coronary angioplasty in patients with acute myocardial infarction. Amer Heart J 131: 219-223, 1996.
82. Freeman, E.J., Chisolm, G.M., Ferrario, C.M., and Tallant, E.A.: Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 28: 104-108, 1996.
83. Chai YC, Howe PH, DiCorleto PE, and Chisolm GM. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells: evidence for release of FGF 2. J Biol Chem. 271:17791-17797, 1996.
84. Colles SM, Irwin KC, and Chisolm GM. Roles of multiple oxidized LDL lipids in cellular injury: Dominance of 7-?-hydroperoxycholesterol. J Lipid Res. 37: 2018-2028, 1996.
85. Gottsauner-Wolf M, Y Jang, MS Penn, A Kaplan, SG Ellis, GM Chisolm, EJ Topol, AM Lincoff. Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. Cathet Cardiovasc Diagn. 42:102-108, 1997.
86. Chisolm GM, Colles SM, Chai Y-C. The effects of oxidized lipids and lipoproteins on arterial growth, remodeling and restenosis. In: "Arterial Remodeling: A Critical Factor in Restenosis", Editors: Lafont A, Topol EJ. Kluwer Academic Publishers. Boston. PP 389-406, 1997.
87. Ananyeva NM, Tjurmin AV, Berliner JA, Chisolm GM, Liau G, Winkles JA, and Haudenschild CC. Oxidized LDL mediates the release of Fibroblast Growth Factor-1. Arterioscler, Thromb, Vasc Biol. 17: 445-453, 1997.
88. Rangaswamy S, Penn MS, Saidel GM, Chisolm GM. Exogenous oxidized low density lipoprotein injures and alters the barrier function of endothelium in rats in vivo. Circ Res. 80: 37-44, 1997.
89. Penn MS, Rangaswamy S, Saidel GM, Chisolm GM. Macromolecular transport in the arterial intima: comparison of chronic hypertension and lipopolysaccharide induced injuries. Amer. J. Physiol: Heart and Circ. Physiol. 41: H1560-1570, 1997.
90. Lesoon A, Mehta A, Singh R, Chisolm GM, and Driscoll DM. An RNA-binding protein recognizes a mammalian SECIS element required for cotranslational incorporation of selenocysteine. Mol. Cell Biol. 17: 1977-1985, 1997.
91. Rong JX, Rangaswamy S, Shen LJ, Dave R, Chang YH, Peterson H, Hodis HN, Chisolm GM, Sevanian A. Arterial injury by cholesterol oxidation products causes endothelial dysfunction and arterial wall cholesterol accumulation. Arterioscler, Thromb and Vasc Biol, 18: 1885-94, 1998.
92. Schmitt D, Shen Z, Zhang R, Colles SM, Wu W, Salomon R, Chen Y, Chisolm GM, Hazen SL. Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry 38: 16904-15, 1999.
93. Penn MS, Patel CV, Cui M-Z, DiCorleto PE, Chisolm GM. LDL increases inactive tissue factor on vascular smooth muscle cell surfaces; hydrogen peroxide activates latent cell surface tissue factor. Circulation 99: 1753-9, 1999.
94. Cui M-Z, Penn MS, Chisolm GM. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J Biol Chem 274:32795-802, 1999.
95. Chisolm GM, Hazen SL, Fox PL, Cathcart MK. The oxidation of lipoproteins by monocytes-macrophages: biochemical and biological mechanisms. J Biol Chem 274:25959-62, 1999.
96. Chisolm GM, Chai Y-C. Regulation of cell growth by oxidized LDL. Free Radical Biology and Medicine, 28:1697-707, 2000.
97. Chai Y-C, Binion DG, Chisolm GM. Relationship of molecular structure to the mechanism of lysophospholipid-induced smooth muscle cell proliferation. Amer J Physiol: Heart and Circ Physiol, 279:H1830-8, 2000.
98. Colles SM, Chisolm GM. Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J Lipid Res, 41:1188-98, 2000.
99. Penn MS, Cui M-Z, Winokur AL, Bethea J, Hamilton TA, DiCorleto PE, Chisolm GM. Smooth muscle cell surface tissue factor pathway activation by oxidized LDL requires cellular lipid peroxidation. Blood, 96:3056-63, 2000.
100. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherosclerosis: An overview. Free Radical Biology and Medicine, 28:1815-26, 2000.
101. Chen Q, Chai Y, Mazuder S, Drazba J, Chisolm G, Almasan A. The late increase of free radicals during genotoxic-stress induced apoptosis is associated with cytochrome C release from mitochondria induced by Caspase-mediated feedback loop amplification. ScientificWorldJournal. 2001 Jan 1;1(1 Suppl 3):142.
102. Colles SM, Maxson JM, Carlson SG, Chisolm GM. Oxidized LDL-induced injury and apoptosis in atherosclerosis; potential roles for oxysterols. Trends in Cardiovascular Medicine, 11:131-8, 2001.
103. Chai Y-C, Binion DG, Macklis R, Chisolm GM. Smooth muscle cell proliferation induced by oxidized LDL-borne lysophosphatidylcholine: evidence for FGF-2 release from cells not extracellular matrix. Vascular Pharmacology, 38:229-37, 2002.
104. Yen MH, Pilkington G, Starling RC, Ratliff NB, McCarthy PM, Young JB, Chisolm GM, Penn MS. Increased tissue factor expression predicts development of cardiac allograft vasculopathy. Circulation, 106:1379-83, 2002.
105. Xu X, Shi Y-C, Gao W, Mao G, Zhao G, Agrawal S, Chisolm GM, Sui D, Cui M-Z. The novel presenilin-1-associated protein (PSAP) is a pro-apoptotic mitochondrial protein. J Biol Chem, 277:48913-48922, 2002.
106. Hazen SL, Chisolm GM. Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. Proc Natl Acad Sci USA. 99:12515-17, 2002.
107. Agrawal S, Agarwal ML, Chatterjee-Kishore M, Stark GR, Chisolm GM. Stat1-dependent, p53-independent expression of p21waf1 modulates oxysterol-induced apoptosis. Mol Cell Biol, 22:1981-92, 2002.
108. Murugesan GM, Sandhya Rani MR, Gerber CE, Mukhopadyay C, Ransohoff RM, Chisolm GM, Kottke-Marchant K. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J Molec Cellular Cardiol, 35:1375-1384, 2003.
109. Cui M-Z, Zhao G,. Winokur AL, Laag E, Bydash JR, Penn MS, Chisolm GM, Xu X. Lysophosphatidic acid induces tissue factor expression in aortic smooth muscle cells. Arterioscler Thromb Vasc Biol, 23:224-30, 2003.
110. Chen Q, Chai Y-C, Mazumder S, Jiang C, Macklis RM, Chisolm GM, Almasan A. The late increase in free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation and mitochondrial dysfunction. Cell Death & Differentiation, 10:323-34, 2003.
111. Penn MS, Chisolm GM. Lipoprotein oxidation, inflammation and atherosclerosis. Chapter 8 in: "Atherothrombosis and Coronary Artery Disease" 2nd Ed. Fuster V, Topol EJ, Nabel EG, Eds. Lippincott Williams & Wilkins, Philadelphia, pages 111-122, 2005.
ACTIVE RESEARCH SUPPORT
NIH/NHLBI: P01 HL29582 (Project 1 of a Program Project: "Oxidation, vascular cell function and atherosclerosis", P. DiCorleto, Program Director)
7/1/03 - 6/30/08
"Project 1: Cell injury by oxidized LDL in vitro and in vivo"
The major goals of Project 1 are to determine cellular mechanisms of oxysterol-induced apoptosis, including the pro-apoptotic effects of Stat1 mediated signaling pathways, and the anti-apoptotic mechanisms mediated by the antioxidant selenoenzyme, phospholipid hydroperoxide glutathione peroxidase. These are examined in vitro and in vivo, the latter in genetically-altered atherosclerosis-susceptible mouse models.
GMC role: Project Leader/Project 1; Percent effort: 40%
Current Year Annual Direct Costs for Project 1: $265,739
NIH/NIA: K01 AG01040 (Mentored Res Sci Devel Award in Aging) P.I.: Sara G. Carlson, Ph.D., Res. Assoc.
6/1/01 - 5/31/06
"Antioxidant protection in age-associated atherosclerosis"
These studies are to define specific aspects of the role of reactive oxygen species in endothelial cell apoptosis and to examine the role of this process in age-associated atherosclerosis in the senescence-accelerated mouse compared to control mice.
GMC role: Mentor (Percent effort not specified; ~5 to 10%)
Current Year Annual Direct Costs: $78,110
NIH/NCI: CA56937 R01 P.I.: James Finke, Ph.D., Staff, Department of Immunology
9/1/03 - 8/31/08
"T Cell Unresponsiveness in Human Tumors"
GMC role: Coinvestigator
Partial salary support
SELECTED INVITED PRESENTATIONS AT NATIONAL OR INTERNATIONAL SCIENTIFIC MEETINGS
(Not included in CV are invited presentations at corporate or other academic institutions or presentations at national or international meetings selected from submitted abstracts.)
Minisymposium on Lipoprotein Arterial Wall Interactions; Houston, TX; November, 1979.
Blood Vessel Club, FASEB Meeting; Chicago, IL; April, 1983.
Workshop on Dietary Lipids and Atherogenesis: New Concepts; University of Texas Health Sciences Center, Dallas, TX; September, 1985.
Symposium on Perspectives in Endothelial Cell Biology; NHLBI; December, 1985.
Gordon Conference on Arteriosclerosis; Meriden, NH; June, 1987.
ACEMB meeting symposium on Transport Processes in the Cardiovascular System; Niagara Falls; September, 1987.
FASEB meeting minisymposium on Atherosclerosis: Cellular and Molecular Mechanisms; Washington, D.C.; March, 1987.
Merrell-Dow Pharmaceuticals Symposium on Insights into the Mechanisms of Action of Probucol; Cincinnati, OH; March, 1987.
Second International Conference on Hypercholesterolemia: Examining New Data on Probucol after a Decade of Use. Los Angeles, CA; November, 1987.
Hypertension and Lipid Metabolism in Vascular Disease; NHLBI Workshop; June, 1988.
World Congress on Medical Physics and Biomedical Engineering; San Antonio, TX; August, 1988.
Eighth Senri Seminar; Osaka, Japan; September, 1988.
Symposium on Modified Lipoproteins; Venice, Italy; October, 1988.
Eighth International Symposium on Atherosclerosis; Rome, Italy; October, 1988.
Gordon Research Conference on Oxygen Radicals in Biology; Ventura, CA; February, 1988.
Twenty-third International Research Symposium of the American Diabetes Association; Hilton Head, SC; March, 1988.
Conference on Nutrient Modulation of Renal Injury" (organized by NIH); Airlie, VA; April, 1989.
Ninth Senri Seminars; Seattle, WA; September, 1989.
Tenth International Symposium on Drugs Affecting Lipid Metabolism; Houston, TX; November, 1989.
Symposium on the Mode of Action of Hypocholesterolemic Agents; FASEB meeting; Washington, D.C., April, 1990.
Twenty-third Annual Hugh Lofland Conference. San Antonio, TX, May, 1990.
Gordon Research Conference on Lipid Metabolism. Meriden, NH, June, 1990.
Cardiology Roundtable on New Research on Prevention and Regression of Atherosclerosis. Kansas City, MO, June, 1990.
International Society for Free Radical Research, Fifth Biennial Meeting, Oxidative Damage and Repair. Pasadena, CA, November, 1990.
American Society for Cell Biology, Subgroup Meeting on Immunoregulatory properties of plasma lipoproteins. San Diego, CA, December, 1990.
Baylor College of Medicine sponsored meeting on Atherosclerosis: a Decade in Perspective. Kauai, HI, January, 1991.
Hugh Lofland Symposia on Atherosclerosis 1991. Seattle, WA, May, 1991.
Gordon Research Conference on Atherosclerosis. Meriden, NH, June, 1991.
International Diabetes Federation Satellite Symposium on Macrovascular Complications of Diabetes Mellitus." Charleston, SC, June, 1991.
14th International Diabetes Federation Congress (American Diabetes Association). Washington, D.C., June, 1991.
Ninth International Symposium on Atherosclerosis. Rosemont-Chicago,IL, October 6-11, 1991.
Atherosclerosis Roundtable (Sponsored by Bristol-Myers Squibb Company). Princeton, NJ, November 6, 1991.
Third International Symposium on Lipids and Atherosclerosis, Madrid, Spain, April 3-4, 1992.
Restenosis Summit IV, Cleveland, OH, May 28-29, 1992.
Sixth Biennial Meeting of the International Society for Free Radical Research. Torino, Italy, June 16-20, 1992.
Second International Symposium on Multiple Risk Factors in Cardiovascular Disease, Osaka, Japan, October 5-8, 1992.
Midwest Lipid Working Group Meeting, Washington University (spon), St. Louis, MO, September 18-19, 1992.
Symposium on Cardiovascular Reactivity and Atherosclerosis: Emerging Clinical and Scientific Developments, SUNY (spon), Buffalo, NY, November 5, 1992.
Symposium on Dietary Lipids, Antioxidants, and the Prevention of Atherosclerosis, University of Udine (spon), Asolo, Italy, December 7-9, 1992.
The Collaborators meeting of the Digitalis Investigation Group (NIH spon), Baltimore, MD, February 27, 1993.
Symposium on New Frontiers in Atherosclerosis and Lipoprotein Metabolism, Baylor College of Medicine (spon), Houston, TX May 7-8, 1993.
Symposium on Atherosclerosis and Lipoprotein Metabolism, Johns Hopkins University (spon), Baltimore, MD, May 13-14, 1993.
Restenosis Summit IV, Cleveland, OH, May 20-21, 1993.
Symposium Frontiers in Lipid and Lipoprotein Research: Basic Science, Analytical and Clinical Application, Atlanta, GA, September 19-21, 1993.
U.S.-Poland Symposium on Cardiopulmonary Diseases, NHLBI (U.S. sponsor), Warsaw, Poland, October 11-13, 1993.
Annual Meeting of the Biomedical Engineering Society, Memphis, TN, October, 22-24, 1993.
FDA Public Conference on Antioxidant Nutrients and Cancer and Cardiovascular Disease, Washington, D.C., November 1-3, 1993.
Lipid Council Meeting, Rome, Italy, November 27-28, 1993.
IBC Second Annual Conference on Atherosclerosis, Philadelphia, PA, February 10, 1994.
International Symposium on Free Radicals in Biology. (Satellite symposium to the XVI International Congress of Biochemistry and Molecular Biology), Chandigarh, India, September 15-17, 1994.
Symposium on Modified Lipoproteins, Vancouver, B.C., Canada, October 6-8, 1994. (A Satellite Symposium to the International Atherosclerosis Symposium in Montreal.)
Satellite Symposium on Diabetes, Obesity and Atherosclerosis, Toronto, Canada, October 14-16, 1994. (A Satellite Symposium to the International Athersclerosis Symposium in Montreal.
Program on Oxidized LDL, Antioxidants and Coronary Artery Disease, American Heart Association 67th Scientific Sessions, Dallas, TX, November 13, 1994.
Plenary Session of the National Thrombosis and Hemostasis Conference, American Heart Association 67th Scientific Sessions, Dallas, TX, November 15, 1994.
Pittsburgh Lipid Club, Pittsburgh, PA, December 1, 1994.
Restenosis Summit VIII, Cleveland, OH, May 17, 1995.
64th Congress of the European Atherosclerosis Society, Utrecht, the Netherlands, June 10-13, 1995.
Searle Atherosclerosis Symposium, St. Louis, MO, September 29, 1995.
Annual International Symposium of the Brazilian Society of Biochemistry, Caxambu, Brazil, May 5, 1996.
IXth International Vascular Biology Meeting, Seattle, WA, September 6, 1996.
American Diabetes Association Symposium on the Role of Oxidants and Antioxidant Therapy in Diabetic Complications, Orlando, FL, November 16, 1996.
International Symposium on Vitamin E, Kyoto, Japan, February 25, 1997.
Fourth International Symposium on Multiple Risk Factors in Cardiovascular Disease, Washington, DC, April 23, 1997.
Oxygen Club of California '99 World Congress, Santa Barbara CA, March 3-6, 1999.
73rd Scientific Sessions of the American Heart Association, New Orleans LA, November 12, 2000.
Second Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Arlington VA, May 12, 2001.
Keystone Meeting on "Inflammatory Paradigms and the Vasculature II. Steamboat Springs, CO, April 9-14, 2002.
XXVIII Nordic Congress in Clinical Biochemistry and the XXXV Nordic Conference in Coagulation. Reykjavik, Iceland, August 10-13, 2002.
XIII International Symposium on Atherosclerosis, Kyoto, Japan, September 28-October 2, 2003.
Satellite Symposium on "Vascular Remodeling in Atherosclerosis and Restenosis", (Satellite to the International Symposium on Atherosclerosis in Kyoto, above), Kobe, Japan, October 3-4, 2003.
South East Lipid Research Conference, Callaway Gardens, Pine Mountain GA, September 24-26, 2004.
SESSION CHAIRMANSHIPS AND PLANNING COMMITTEES FOR SCIENTIFIC MEETINGS
Session Chairman: "Atherosclerosis" session at American Institute of Chemical Engineers. Chicago, IL, December, 1980.
Session Chairman: "Arteriosclerosis: Cellular Aspects of Lipoprotein Metabolism". 59th Scientific Sessions, American Heart Association. Dallas, TX, November, 1986.
Session Chairman: "Arteriosclerosis: Modified Lipoproteins." At: 63rd Scientific Sessions, American Heart Association. Dallas, TX, November, 1990.
Session Chairman: "Minisymposium on Atherosclerosis." At: FASEB meeting. Atlanta, GA, April, 1991.
Session Chairman: "Lipids and Atherosclerosis." At: 24th Hugh Lofland Atherosclerosis Conference. Seattle, WA, May, 1991.
Planning Committee for international meeting: "Antioxidant Therapy and Atherosclerotic Disease." Session Co-chairman and presenter "LDL modification in vivo." Sponsored by NIH; Washington, DC, September, 1991.
Session Co-chairman for discussion group: "Avoiding Conflict of Interest." At: NIH Director's Chairpersons Meeting (to evaluate NIH Peer Review). Bethesda, MD, January 17, 1992.
Session Chairman, Minisymposium on Atherosclerosis, Experimental Biology (FASEB) Meeting, New Orleans, LA, March 31, 1992.
Session Chair, LDL Modification-I, American Heart Association Sixty Sixth Scientific Sessions, Atlanta, GA, November 9, 1993.
Session Chair, IBC's Second Annual Conference on Atherosclerosis, Philadelphia, PA, February 10, 1994.
Session Chair, Oxidized Lipids/Oxidant Stress, Experimental Biology (FASEB) Meeting, Anaheim, CA, April 27, 1994.
Co-chairman of meeting organization for: Symposium on Modified Lipoproteins, Vancouver BC, Canada, October 6-8, 1994. (A satellite symposium to the International Atherosclerosis Symposium in Montreal).
Organizing committee member, International Symposium on Diabetes Mellitus, Obesity and Hyperlipidemia (A Satellite Symposium to the 15th International Diabetes Foundation Meeting), Kobe, Japan, November 4-5, 1994.
Co-chair of Scientific Session on "Lipoprotein Oxidation and Atherogenesis". At: 68th Annual Sessions of The American Heart Association. Anaheim, CA, November 14, 1995.
Co-chair of Scientific Session on "Lipids and Lipoproteins". At: Joint Meeting of the Amer Society for Biochem and Molecular Biol, Amer Soc for Invest Pathol, and Amer Assoc of Immunologists. New Orleans, LA, June 4, 1996.
Chair of Scientific Session on "LDL Oxidation and Atherosclerosis". At: International Symposium on Vitamin E. Kyoto, Japan, February 25, 1997.
Chair and organizer of "The Blood Vessel Club '97". Held in conjunction with the annual international meetings of Vascular Biology '97 and Experimental Biology '97. New Orleans, LA, April 6, 1997.
Moderator for session on "Restricting Youth Access to Tobacco"; Federation for Community Planning. Cleveland, OH, April 9, 1998.
Chair of Minisymposium on "Atherosclerosis and Restenosis" at Experimental Biology '98. San Francisco, CA, April 19, 1998.
Co-chair of Symposium on "Endothelium" at Molecular Medicine 2002, the XXVIII Nordic Congress in Clinical Biochemistry and the XXXV Nordic Conference in Coagulation. Reykjavik, Iceland, August 10-13, 2002
Program Committee for the 2003 meeting of the North American Vascular Biology Organization, San Diego, CA, April, 2003.
Chairman (and organizer) of Symposium "New Paradigms in Atherosclerosis", for the 2003 meeting of the North American Vascular Biology Organization, San Diego, CA, April 12, 2003.
TEACHING
At the University of Virginia:
As a grad student: teaching assistant and taught introductory computer programming to freshmen in the engineering school, 1970-1971
As a visiting professor: Three-week intensive course (30 hours of lecture) in applied engineering mathematics to chemistry graduates beginning graduate school in Chemical Engineering, summer, 1976
At Case Western Reserve University:
Department of Biomedical Engineering, School of Engineering and School of Medicine, Case Western Reserve University:
To CWRU's medical students: Cardiovascular physiology laboratory. Three sessions/year, 1976 through 1988
To graduate students in the Department of Biochemistry: A course on lipid metabolism. Two lectures/year on lipoprotein biochemistry and metabolism, 1983 and 1984.
To freshmen in the Department of Biomedical Engineering: Introduction to Biomedical Engineering. Two lectures/year on mathematical modeling of physiological systems, 1980 - 1990
To sophomores in the Departments of Biology and Biomedical Engineering: Semester laboratory course in comparative physiology, 1975 - 1978
To juniors and seniors in the Department of Biomedical Engineering: Two-semester laboratory course in all multiple and diverse aspects of Biomedical Engineering. (Started the course, organized it, oversaw it, and taught in it, 1976 through 1985; recently, started participating again, offering a 3-day lab, 2002 - present.)
To seniors in the Department of Biomedical Engineering: A full semester course in mathematical modeling of physiological systems. Fifteen hours of lectures (one-third of the course)/year on compartmental analysis and pharmacokinetics, 1980 - 1986
To sophomores and graduate students in the Department of Biomedical Engineering: One-semester organ systems-based lecture course on Physiology and Biophysics; fifteen hours of lectures (one-third of the course)/year on gastrointestinal physiology and metabolism, for sophomores: 1977 - 1988; for graduate students, 1977 - 1998
At the Cleveland Clinic Foundation:
Lecturer in the annual CCF-sponsored national course, "An Intensive Review of Cardiology". My topic: "Biology of coronary disease for clinicians", 2000 - 2004.
Primary research supervisor for 2 M.S. students and 4 Ph.D. students from CWRU's Department of Biomedical Engineering and 2 Ph.D. students from the Department of Chemistry, Cleveland State University.
Supervisor for over 15 postdoctoral trainees.
Research oversight committees of several Ph.D. students at CWRU (Depts of Biomedical Engineering, Physiology & Biophysics and Biochemistry) and CSU (Depts of Biology and Chemistry).
At the Cleveland Clinic Lerner College of Medicine (CCLCM) of Case School of Medicine (see also INSTITUTIONAL SERVICE below):
Organizer, Summer Session Journal Club, 2003 - present
Research Preceptor/Mentor for first year student, summer, 2004; summer, 2005
Research presentation in Process of Discovery series, 2004
Seminar on fat digestion/absorption, 2005
Seminar on lipoprotein metabolism, 2005
At Cleveland State University:
To graduate students in Clinical Chemistry, occasional lectures in courses and seminars on inflammation and atherosclerosis disease mechanisms (1996 - present)
INSTITUTIONAL SERVICE
At Case Western Reserve University (1975 - present):
1975-85:
Multiple CWRU committees at the Department (Biomedical Engineering), School (Engineering and Medicine) and University levels, 1975 to 1985. These committees related to graduate student admissions, awarding of merit scholarships, overseeing or developing curricula, etc.
Research ShowCASE Steering Committee (annual event at Case to feature academic atmosphere)
Recent:
Research ShowCASE Steering Committee (annual event at Case to feature academic environment), 2004-present
Case Advisory Committee on Conflict of Interest, 2004-present
Case School of Medicine Dean's Ad Hoc Committee on Institutional Conflict of Interest, 2005-present
At the Cleveland Clinic Foundation (1985 to the present):
Board of Governors, Cleveland Clinic Foundation (elected 5 year term), 1998 - 2002
Board of Trustees, Cleveland Clinic Foundation, 2001 - 2002
Board of Trustees Research and Education Committee 2001 - present
Board of Trustees Executive Committee, 2002
Board of Governors Task Force to Reorganize Research Structure, 2000-2001
Board of Trustees Task Force on Conflict of Interest, Co-Chair, 2004-present
Board of Governors Task Force to Review Ethical and Legal ("YellowBook") Guidelines for CCF, 2005
Vice Chairman, Lerner Research Institute, 2003 - present
Interim Chairman, Department of Cell Biology, 8/2002 - 4/2004
Research Division Committee of the Lerner Research Institute, 2002 - present
Executive Committee of the Lerner Research Institute, 2000 - 2002
Committee on Appointments and Promotions for the Lerner Research Institute, 1991 - 2002
Committee on Appointments and Promotions, Dept of Biostats and Epidemiol, 1998 - 2003; Chair, 1998 - 2000
Research Programs Committee, 1986 - 1990
LRI Task Force to develop joint Ph.D. programs with CWRU, 1993 - 1996
Coordinator of Graduate Studies for LRI, 1995 - 1998
Steering Committee for educational programs with Morehouse School of Medicine, Atlanta, 1993 - present
LRI Steering Committee for joint Ph.D. program with Dept of Chem, Cleve State Univ, 1996 - present
Educational Governing Group, 1995 - 1999
Conflict of Interest Committee for CCF, 2003 - present, Chair
Scientific Quality and Conduct Committee for CCF, 1990 - present; 1994 - present, Chair
Animal Research Committee (IACUC) for CCF, 1986 - 1990, Chair
Radiation Safety Committee for CCF, 1988 - 1997, 1992 - 1997, Chair
Staff Satisfaction Committee for CCF, 2003 - present
CCF Innovations Council, 2000 - present
Multiple search committees for new Staff (faculty) positions in the Lerner Research Institute, ongoing
Search Committee for Molecular Medicine Staff, 2005-present, Chair
Radiation Safety Executive Committee for CCF, 1997 - present
Committee for Staff Diversity for CCF, 1995 - present
Biosafety Committee for CCF, 1985 - 1986
Internet Strategy Committee (and Chairman of Research Subcommittee) for CCF, 2001
Commission for Biomedical Engineering in Northeast Ohio, (joint with CWRU, CSU), 2001
North Shore Alliance for Graduate Study and Research (research and education partnership among CSU, KSU, AU, YSU, CCF)
Selection Committee for the Tarazi Prize in CCF Cardiovascular Research, 1993 - present; Chair: 1997 - present
Selection Committee for Elsa Albrecht prize for research in Cell Biology at CCF, 1993 - 1994
Selection Committee for Razavi CCF Clinical Scholar Award, 1998 - 2001
Selection Committee for the Wilson Award [research grants]
Nominating Committee of the Board of Governors (elected annually by CCF Staff), 1994-5, 1996-7, 2002-3 Co-Chair, 2003-4
Board of Governors Search Committee for Chairman, Department of Musculoskeletal Research, 1988
Board of Governors Search Committee for Chairman, Department of Biostatistics, 1993
Board of Governors Search Committees for Chairman, Dept. of Vascular Medicine 1995, 1997, 2001, Chair
Board of Governors Search Committee for Chairman, Taussig Cancer Center, 2003
Board of Governors Committee to review leadership of the Chairman, Division of Lab Medicine (Pathol), 1990
Board of Governors Committee to review leadership of the Chairman, Division of Surgery, 1992
Board of Governors Committee to review leadership of the Chairman, Division of Medicine, 1997
Board of Governors Committee to review leadership of the Chairman, Dept of Brain and Vasc Res, 1991
Board of Governors Committee to review leadership of the Chairman, Dept of Nuclear Medicine, 1991
Board of Governors Committee to review leadership of the Chairman, Dept of Radiation Oncology, 1999, Chair
Board of Governors Committee to review leadership of the Chairman, Dept of Dentistry, 2001, Chair
Board of Governors Committee to review leadership of the Chairman, Dept of Clinical Pathology, 2002, Chair
Board of Governors Committee to review leadership of the Chairman, Center for Surgery Research, 2004-2005, Chair
At Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) (2003 - present):
Curriculum Development Committee for Gastrointestinal Organ Systems, 2003 - present
Committee on Appointments and Promotions of CCLCM, 2003 - present
Admissions Committee of CCLCM, 2003 - present
Medical Student Promotions and Review Committee of CCLCM, 2004 - present
CCLCM Molecular Medicine representative, Case School of Medicine Faculty Council
Basic Science Education Co-Director, 2005 - present
Basic Science and Education Committee of CCLCM, Co-Chair, 2005 - present
Curriculum Steering Committee
Physiology Thread Committee of CCLCM, 2005 - present
|
|
|
